#BEGIN_DRUGCARD DB02080

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C21H36O4

# Chemical_IUPAC_Name:
1-[4-(2,4,4-trimethylpentan-2-yl)phenyl]-1,4,7,10-tetraoxaundecane

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene

# HET_ID:
TRT

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C21H36O4/c1-20(2,3)17-21(4,5)18-7-9-19(10-8-18)25-16-15-24-14-13-23-12-11-22-6/h7-10H,11-17H2,1-6H3

# InChI_Key:
InChIKey=HEUDUECKTWTQQR-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2080

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
352.5081

# Molecular_Weight_Mono:
352.26135964

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1OIZ

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
4.81

# Predicted_LogS:
-6.2

# Predicted_Water_Solubility:
2.07e-04 g/l

# Primary_Accession_No:
DB02080

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
446308

# PubChem_Substance_ID:
46506840

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03116

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COCCOCCOCCOC1=CC=C(C=C1)C(C)(C)CC(C)(C)C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:46 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
peripheral membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PLA2G2A

# Drug_Target_1_GenBank_ID_Gene:
M22430

# Drug_Target_1_GenBank_ID_Protein:
190889

# Drug_Target_1_GeneCard_ID:
PLA2G2A

# Drug_Target_1_Gene_Name:
PLA2G2A

# Drug_Target_1_Gene_Sequence:
>435 bp
ATGAAGACCCTCCTACTGTTGGCAGTGATCATGATCTTTGGCCTACTGCAGGCCCATGGG
AATTTGGTGAATTTCCACAGAATGATCAAGTTGACGACAGGAAAGGAAGCCGCACTCAGT
TATGGCTTCTACGGCTGCCACTGTGGCGTGGGTGGCAGAGGATCCCCCAAGGATGCAACG
GATCGCTGCTGTGTCACTCATGACTGTTGCTACAAACGTCTGGAGAAACGTGGATGTGGC
ACCAAATTTCTGAGCTACAAGTTTAGCAACTCGGGGAGCAGAATCACCTGTGCAAAACAG
GACTCCTGCAGAAGTCAACTGTGTGAGTGTGATAAGGCTGCTGCCACCTGTTTTGCTAGA
AACAAGACGACCTACAATAAAAAGTACCAGTACTATTCCAATAAACACTGCAGAGGGAGC
ACCCCTCGTTGCTGA

# Drug_Target_1_General_Function:
Involved in phospholipase A2 activity

# Drug_Target_1_General_References:
1948070	Scott DL, White SP, Browning JL, Rosa JJ, Gelb MH, Sigler PB: Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. Science. 1991 Nov 15;254(5034):1007-10.
2062381	Wery JP, Schevitz RW, Clawson DK, Bobbitt JL, Dow ER, Gamboa G, Goodson T Jr, Hermann RB, Kramer RM, McClure DB, et al.: Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2 A resolution. Nature. 1991 Jul 4;352(6330):79-82.
2239446	Kramer RM, Johansen B, Hession C, Pepinsky RB: Structure and properties of a secretable phospholipase A2 from human platelets. Adv Exp Med Biol. 1990;275:35-53.
2775276	Kanda A, Ono T, Yoshida N, Tojo H, Okamoto M: The primary structure of a membrane-associated phospholipase A2 from human spleen. Biochem Biophys Res Commun. 1989 Aug 30;163(1):42-8.
2925608	Seilhamer JJ, Pruzanski W, Vadas P, Plant S, Miller JA, Kloss J, Johnson LK: Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem. 1989 Apr 5;264(10):5335-8.
2925633	Kramer RM, Hession C, Johansen B, Hayes G, McGray P, Chow EP, Tizard R, Pepinsky RB: Structure and properties of a human non-pancreatic phospholipase A2. J Biol Chem. 1989 Apr 5;264(10):5768-75.
3202859	Lai CY, Wada K: Phospholipase A2 from human synovial fluid: purification and structural homology to the placental enzyme. Biochem Biophys Res Commun. 1988 Dec 15;157(2):488-93.
3240982	Hara S, Kudo I, Matsuta K, Miyamoto T, Inoue K: Amino acid composition and NH2-terminal amino acid sequence of human phospholipase A2 purified from rheumatoid synovial fluid. J Biochem (Tokyo). 1988 Sep;104(3):326-8.
7664108	Schevitz RW, Bach NJ, Carlson DG, Chirgadze NY, Clawson DK, Dillard RD, Draheim SE, Hartley LW, Jones ND, Mihelich ED, et al.: Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol. 1995 Jun;2(6):458-65.
8399335	Minami T, Tojo H, Shinomura Y, Matsuzawa Y, Okamoto M: Purification and characterization of a phospholipase A2 from human ileal mucosa. Biochim Biophys Acta. 1993 Oct 13;1170(2):125-30.
9538252	Kitadokoro K, Hagishita S, Sato T, Ohtani M, Miki K: Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032. J Biochem (Tokyo). 1998 Apr;123(4):619-23.

# Drug_Target_1_HGNC_ID:
HGNC:9031

# Drug_Target_1_HPRD_ID:
01397

# Drug_Target_1_ID:
2981

# Drug_Target_1_Locus:
1p35

# Drug_Target_1_Molecular_Weight:
16083

# Drug_Target_1_Name:
Phospholipase A2, membrane associated

# Drug_Target_1_Number_of_Residues:
144

# Drug_Target_1_PDB_ID:
1DB4

# Drug_Target_1_Pathway:
Abciximab Pathway	SMP00265
Acetylsalicylic Acid Pathway	SMP00083
Bromfenac Pathway	SMP00102
Celecoxib Pathway	SMP00096
Cilostazol Pathway	SMP00263
Clopidogrel Pathway	SMP00260
Diclofenac Pathway	SMP00093
Diflunisal Pathway	SMP00289
Dipyridamole (Antiplatelet) Pathway	SMP00264
Eptifibatide Pathway	SMP00266
Etodolac Pathway	SMP00084
Ibuprofen Pathway	SMP00086
Indomethacin Pathway	SMP00104
Ketoprofen Pathway	SMP00085
Ketorolac Pathway	SMP00098
Mefanamic Acid Pathway	SMP00109
Meloxicam Pathway	SMP00106
Nabumetone Pathway	SMP00114
Naproxen Pathway	SMP00120
Oxaprozin Pathway	SMP00113
Piroxicam Pathway	SMP00077
Rofecoxib Pathway	SMP00087
Sulindac Pathway	SMP00094
Suprofen Pathway	SMP00101
Ticlopidine Pathway	SMP00261
Tirofiban Pathway	SMP00267
Valdecoxib Pathway	SMP00116

# Drug_Target_1_Pfam_Domain_Function:
PF00068	Phospholip_A2_1

# Drug_Target_1_Protein_Sequence:
>Phospholipase A2, membrane associated precursor
MKTLLLLAVIMIFGLLQAHGNLVNFHRMIKLTTGKEAALSYGFYGCHCGVGGRGSPKDAT
DRCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQLCECDKAAATCFAR
NKTTYNKKYQYYSNKHCRGSTPRC

# Drug_Target_1_Reaction:
phosphatidylcholine + H2O = 1-acylglycerophosphocholine + a carboxylate

# Drug_Target_1_Signals:
1-20

# Drug_Target_1_Specific_Function:
Thought to participate in the regulation of the phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2- acyl groups in 3-sn-phosphoglycerides

# Drug_Target_1_SwissProt_ID:
P14555

# Drug_Target_1_SwissProt_Name:
PA2GA_HUMAN

# Drug_Target_1_Synonyms:
EC 3.1.1.4
GIIC sPLA2
Group IIA phospholipase A2
NPS-PLA2
Non-pancreatic secretory phospholipase A2
Phosphatidylcholine 2-acylhydrolase
Phospholipase A2, membrane associated precursor

# Drug_Target_1_Theoretical_pI:
9.51

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cell inner membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
K00426

# Drug_Target_2_GenBank_ID_Protein:
146600

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
lepB

# Drug_Target_2_Gene_Sequence:
>972 bp
ATGGCGAATATGTTTGCCCTGATTCTGGTGATTGCCACACTGGTGACGGGCATTTTATGG
TGCGTGGATAAATTCTTTTTCGCACCTAAACGGCGGGAACGTCAGGCAGCGGCGCAGGCG
GCTCGGGACTCACTGGATAAAGCAACGTTGAAAAAGGTTGCGCCGAAGCCTGGCTGGCTG
GAAACCGGTGCTTCTGTTTTTCCGGTACTGGCTATCGTATTGATTGTGCGTTCGTTTATT
TATGAACCGTTCCAGATCCCGTCAGGTTCGATGATGCCGACTCTGTTAATTGGTGATTTT
ATTCTGGTAGAGAAGTTTGCTTATGGCATTAAAGATCCTATCTACCAGAAAACGCTGATC
GAAAACGGTCATCCGAAACGCGGCGATATCGTGGTCTTTAAATATCCGGAAGATCCAAAG
CTTGATTACATCAAGCGCGCGGTCGGTTTACCGGGCGATAAAGTCACTTACGATCCGGTC
TCAAAAGAGCTGACGATTCAACCGGGATGCAGTTCCGGCCAGGCGTGTGAAAACGCGCTG
CCGGCTACCTACTCAAACGTGGAACCGAGCGATTTCGTTCAGACCTTCTCACGCCGTAAT
GGTGGGGAAGCGACCAGCGGATTCTTTGAAGTGCCGAAAAACGAAACCAAAGAAAATGGA
ATTCGTCTTTCCGAGCGTAAAGAGACACTGGGTGATGTGACGCACCGCATTCTGACAGTG
CCGATTGCGCAGGATCAGGTGGGGATGTATTACCAGCAGCCAGGGCAACAACTGGCAACC
TGGATTGTTCCTCCGGGACAATACTTCATGATGGGCGACAACCGCGACAACAGCGCGGAC
AGCCGTTACTGGGGCTTTGTGCCGGAAGCGAATCTGGTCGGTCGGGCAACGGCTATCTGG
ATGAGCTTCGATAAGCAAGAAGGCGAATGGCCGACTGGTCTGCGCTTAAGTCGCATTGGC
GGCATCCATTAA

# Drug_Target_2_General_Function:
Intracellular trafficking, secretion, and vesicular transport

# Drug_Target_2_General_References:
1546969	Black MT, Munn JG, Allsop AE: On the catalytic mechanism of prokaryotic leader peptidase 1. Biochem J. 1992 Mar 1;282 ( Pt 2):539-43.
1618816	Sung M, Dalbey RE: Identification of potential active-site residues in the Escherichia coli leader peptidase. J Biol Chem. 1992 Jul 5;267(19):13154-9.
2202591	Bilgin N, Lee JI, Zhu HY, Dalbey R, von Heijne G: Mapping of catalytically important domains in Escherichia coli leader peptidase. EMBO J. 1990 Sep;9(9):2717-22.
2551889	San Millan JL, Boyd D, Dalbey R, Wickner W, Beckwith J: Use of phoA fusions to study the topology of the Escherichia coli inner membrane protein leader peptidase. J Bacteriol. 1989 Oct;171(10):5536-41.
6311837	Wolfe PB, Wickner W, Goodman JM: Sequence of the leader peptidase gene of Escherichia coli and the orientation of leader peptidase in the bacterial envelope. J Biol Chem. 1983 Oct 10;258(19):12073-80.
8394311	Black MT: Evidence that the catalytic activity of prokaryote leader peptidase depends upon the operation of a serine-lysine catalytic dyad. J Bacteriol. 1993 Aug;175(16):4957-61.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9823901	Paetzel M, Dalbey RE, Strynadka NC: Crystal structure of a bacterial signal peptidase in complex with a beta-lactam inhibitor. Nature. 1998 Nov 12;396(6707):186-90.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2421

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
35961

# Drug_Target_2_Name:
Signal peptidase I

# Drug_Target_2_Number_of_Residues:
324

# Drug_Target_2_PDB_ID:
1T7D

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00717	Peptidase_S24

# Drug_Target_2_Protein_Sequence:
>Signal peptidase I
MANMFALILVIATLVTGILWCVDKFFFAPKRRERQAAAQAAAGDSLDKATLKKVAPKPGW
LETGASVFPVLAIVLIVRSFIYEPFQIPSGSMMPTLLIGDFILVEKFAYGIKDPIYQKTL
IETGHPKRGDIVVFKYPEDPKLDYIKRAVGLPGDKVTYDPVSKELTIQPGCSSGQACENA
LPVTYSNVEPSDFVQTFSRRNGGEATSGFFEVPKNETKENGIRLSERKETLGDVTHRILT
VPIAQDQVGMYYQQPGQQLATWIVPPGQYFMMGDNRDNSADSRYWGFVPEANLVGRATAI
WMSFDKQEGEWPTGLRLSRIGGIH

# Drug_Target_2_Reaction:
Cleavage of hydrophobic, N-terminal signal or leader sequences from secreted and periplasmic proteins

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Cleavage of hydrophobic, N-terminal signal or leader sequences from secreted and periplasmic proteins

# Drug_Target_2_SwissProt_ID:
P00803

# Drug_Target_2_SwissProt_Name:
LEP_ECOLI

# Drug_Target_2_Synonyms:
EC 3.4.21.89
Leader peptidase I
SPase I

# Drug_Target_2_Theoretical_pI:
7.43

# Drug_Target_2_Transmembrane_Regions:
4-22
59-77

#END_DRUGCARD DB02080
